Enzastaurin was originally evaluated in human tumour xenograft-bearing mice for its antiangiogenic activity upon PKCβ inhibition, as it showed reduction of plasma VEGF levels together with a significant decrease in intratumoural vessel density (Keyes et al, 2004). Here, VEGFA is linked to neoplasm.